Rezolute, Inc. (NASDAQ:RZLT) Shares Sold by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lowered its holdings in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 7.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,575,000 shares of the company's stock after selling 125,000 shares during the quarter. Rezolute accounts for about 1.0% of Affinity Asset Advisors LLC's portfolio, making the stock its 27th largest position. Affinity Asset Advisors LLC owned about 2.72% of Rezolute worth $7,718,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in RZLT. State Street Corp grew its position in Rezolute by 11.6% in the third quarter. State Street Corp now owns 125,472 shares of the company's stock worth $609,000 after acquiring an additional 13,000 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Rezolute by 67.4% in the 3rd quarter. XTX Topco Ltd now owns 56,375 shares of the company's stock worth $273,000 after purchasing an additional 22,704 shares during the period. MML Investors Services LLC bought a new position in Rezolute during the third quarter valued at $57,000. Geode Capital Management LLC grew its holdings in shares of Rezolute by 39.0% in the third quarter. Geode Capital Management LLC now owns 491,601 shares of the company's stock worth $2,385,000 after purchasing an additional 137,905 shares during the last quarter. Finally, Virtu Financial LLC increased its stake in Rezolute by 58.0% in the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock worth $126,000 after buying an additional 9,551 shares during the period. 82.97% of the stock is owned by hedge funds and other institutional investors.

Rezolute Stock Up 4.2 %

Shares of Rezolute stock traded up $0.11 during trading on Friday, reaching $2.75. The company's stock had a trading volume of 907,137 shares, compared to its average volume of 507,129. Rezolute, Inc. has a 1-year low of $2.22 and a 1-year high of $6.19. The company has a 50-day simple moving average of $3.47 and a two-hundred day simple moving average of $4.49. The company has a market cap of $166.47 million, a price-to-earnings ratio of -2.25 and a beta of 0.97.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.11. As a group, analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

RZLT has been the topic of a number of research analyst reports. JMP Securities raised their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Craig Hallum raised Rezolute to a "strong-buy" rating in a research note on Tuesday, February 4th. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Finally, HC Wainwright reissued a "buy" rating and set a $14.00 price target on shares of Rezolute in a research report on Thursday, February 13th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $26.43.

Insider Activity

In other news, CFO Daron Evans bought 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average price of $2.89 per share, with a total value of $28,900.00. Following the completion of the acquisition, the chief financial officer now directly owns 237,900 shares of the company's stock, valued at $687,531. This trade represents a 4.39 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Nevan C. Elam bought 12,302 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was purchased at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the transaction, the chief executive officer now owns 224,119 shares of the company's stock, valued at $638,739.15. The trade was a 5.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 39,060 shares of company stock valued at $130,694 over the last ninety days. 18.39% of the stock is currently owned by insiders.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.